New Tool: ProSource
Checkout our packaging and processing solutions finder, ProSource.

FDA Approves First Gene Therapy for Hereditary Disease

The FDA has approved Luxturna, a gene therapy that treats patients with an inherited form of vision loss.

Luxturna / Image: Spark Therapeutics
Luxturna / Image: Spark Therapeutics

A December 19th LA Times article reported that the FDA has approved gene therapy to fix mutations that lead to progressive blindness. The drug, Luxturna, is a treatment for retinal dystrophy caused by a genetic mutation. It is the first therapy cleared in the U.S. to treat a genetic disease other than cancer, making it a landmark event.

“Gene therapy will become a mainstay in treating, and maybe curing, many of our most devastating and intractable illnesses,” said Dr. Scott Gottlieb, commissioner of the FDA. “We’re at a turning point when it comes to this novel form of therapy.”

The treatment is injected into the sub-retinal portion of the eye and a normal RPE65 gene is ferried into the patient’s retinal cells by a common cold virus that has been genetically modified to not make the patient sick.

How to Honor a Leader
Induction into the Packaging & Processing Hall of Fame is the highest honor in our industry. Submit your leader to be considered for the Class of 2024 now through June 10th. New members will be inducted at PACK EXPO International in Chicago.
Read More
How to Honor a Leader
Test Your Supply Chain Smarts
Take Healthcare Packaging's supply chain quiz to prove your knowledge!
Read More
Test Your Supply Chain Smarts